HOERSHOLM, Denmark and BOULDER, Colo., Jan. 8, 2013 /PRNewswire/ — Santaris Pharma A/S and miRagen Therapeutics, Inc. today announced that they have expanded their existing partnership in the field of microRNA therapeutics.
Under the expanded agreement, miRagen obtains a broad non-exclusive license in the miRNA therapeutics field for therapeutics research and world-wide exclusive rights to research, develop and commercialize LNA drugs against up to six additional microRNA targets that have been shown to be important in human disease areas of high unmet need. This brings the total number of microRNA targets under the agreement to ten. Santaris Pharma A/S will receive a combination of cash and equity in consideration for the licenses as well as clinical milestones and royalties on products emerging from the alliance. Financial terms were not disclosed.
Henrik Oerum, CSO and VP, Business Development at Santaris Pharma A/S stated: “Our collaboration with miRagen is an important part of our corporate strategy in the microRNA therapeutics field, so we are very [click to continue…]
Court Focuses Patent Suit on Santaris’s Safe Harbor Defense
HOERSHOLM, Denmark and SAN DIEGO, Sept. 24, 2012 /PRNewswire/ — Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the federal court in the Southern District of California granted Santaris significant relief in the patent infringement lawsuit brought by Isis.
The Court stayed all discovery in the case except for discovery specifically related to the Safe Harbor issue raised by Santaris’s motion for summary judgment to dismiss the complaint. In that motion, Santaris showed that its accused activities — which use cutting-edge LNA antisense technology — all relate to drug design and development work that are protected by the statutory safe harbor.
The stay ordered by the Court came on the heels of its decision holding that it could not find, as a matter of law, that Santaris’s accused activities were [click to continue…]
HOERSHOLM, Denmark and SAN DIEGO, Jan. 4, 2011 /PRNewswire/ — Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, and Pfizer Inc. (NYSE: PFE), today announced that the companies have expanded their collaboration directed to the development and commercialization of RNA-targeted medicines using Santaris Pharma A/S Locked Nucleic Acid (LNA) Drug Platform.
The Santaris Pharma A/S LNA Drug Platform is the only RNA technology with both mRNA and microRNA targeted drugs in clinical trials, demonstrating the broad utility of the proprietary platform. The unique combination of small size and high affinity achievable with Santaris Pharma A/S LNA technology allows LNA-based drugs to potently and specifically inhibit RNA targets in different tissues without the need for complex delivery vehicles.
(read the entire release… )
Santaris Pharma A/S announced today that it has advanced miravirsen (SPC3649), a microRNA targeted drug for treatment of Hepatitis C virus (HCV) infection into Phase 2 studies to assess the safety and tolerability of the drug.
Santaris Pharma A/S also received acceptance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA). In addition to the United States, the Phase 2a clinical trials will be conducted in the Netherlands, Germany, Poland, Romania, and Slovakia.
Miravirsen is a specific inhibitor of miR-122, a liver specific microRNA that the Hepatitis C virus requires for replication. Miravirsen is designed to recognize and sequester miR-122, making it unavailable to the Hepatitis C virus. As a result, the replication of the virus is effectively inhibited and the level of Hepatitis C virus is reduced.
In addition to miravirsen, Santaris Pharma A/S is developing other drugs targeting mRNAs and microRNAs both internally as well as in partnerships and collaborations with miRagen Therapeutics (cardiovascular diseases), Shire plc (rare genetic disorders), Pfizer (undisclosed therapeutic areas), GlaxoSmithKline (viral disease) and Enzon Pharmaceuticals (oncology). (read more… )
It’s only a matter of time before the first microRNA therapeutic reaches the market.
Incoming search terms for this article: